NEW YORK, Sept. 18, 2018 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or
"the Company"), announced today that it will unveil a new
clinical initiative that expands the Company's pipeline into the
CAR-T space. CAR-T is a type of cellular therapy that genetically
alters a patient's own T cells to target and kill their cancer
cells. Currently, there are 2 approved CAR-T therapies for patients
with certain B-cell cancers and over 200 CAR-T candidates in
preclinical and clinical development for a wide range of
hematologic and solid tumor indications. Actinium's management team
along with Dr. Nirav Shah, Assistant
Professor of Medicine, Division or Hematology and Oncology at
Froedtert & the Medical College of
Wisconsin will discuss the Companies latest pipeline
initiative, its value proposition as applicable to CAR-T and the
expected development pathway.
Dr. Shah said, "CAR-T is an exciting medical advancement that
has demonstrated incredible promise in patients that need better
treatment options and outcomes. The Froedtert & the
Medical College of Wisconsin was an
early adopter of CAR-T becoming one of the first FACT certified
medical centers in the nation and commercial CAR-T sites,
consistent with its pioneering of other techniques such as stem
cell transplantation and immunotherapy. My colleagues and I, at the
Froedtert & the Medical College of
Wisconsin, are committed to continuing to advance the
exciting field of CAR-T to further improve patient outcomes. I am
excited by the potential of Actinium's next generation technology
to further advance the field of CAR-T and look forward to providing
more details on this potentially disruptive clinical
initiative."
In addition to Dr. Shah, Sandesh
Seth, Actinium's Chairman and CEO and Dr. Dale Ludwig, Actinium's Chief Scientific Officer
will be on the call to discuss this new pipeline initiative.
Participation details for the conference call and webcast are as
follows:
Date: Wednesday, September 26,
2018
Time: 4:15 PM ET
Webcast Registration:
https://onecast.thinkpragmatic.com/ses/8JeRIX31t6pPlM3Dm85kJA~~
U.S. Participant Dial-in: (718) 865-8336
U.S./Canada Toll Free Dial-in: (855) 427-0225
Conference ID: 4831
"We are excited to be forging a path into CAR-T and are thrilled
to be working with Dr. Shah and his colleagues at the Froedtert
& Medical College of Wisconsin who
have been pioneers in this field. We look forward to the
contributions they will make to our next generation technology that
we believe has great potential to advance access to CAR-T and
patient outcomes'" said, Sandesh
Seth, Actinium's Chairman and CEO. "I am incredibly
motivated by this important pipeline expansion which has been
enabled by the efforts of our new team and the potential growth
opportunities it can provide for Actinium."
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a clinical-stage
biopharmaceutical company focused on developing and commercializing
targeted therapies for potentially superior targeted conditioning
of the bone marrow prior to a bone marrow transplant and for the
targeting and killing of cancer cells. The Company's targeted
Antibody Radio-Conjugates (ARCs), combine the targeting ability of
monoclonal antibodies with the cell killing ability of
radioisotopes. Actinium is developing a pipeline of
clinical-stage ARCs targeting CD45 and CD33 for patients with a
broad range of hematologic malignancies.
Iomab-B, Actinium's lead product candidate, is currently
enrolling patients in a pivotal Phase 3 trial. Iomab-B combines the
anti-CD45 monoclonal antibody BC8 labeled with iodine-131 and is
designed to condition the bone marrow prior to a bone marrow
transplant without the need for intense chemotherapy in patients
with relapsed or refractory acute myeloid leukemia (AML) of age 55
or older. Actinium's pipeline also includes a potentially
best-in-class CD33 program with our ARC comprised of the anti-CD33
antibody lintuzumab labeled with the alpha-particle emitter
actinium-225. Its CD33 program is currently being studied in
Phase 2 and Phase 1 clinical trials for patients with AML,
myelodysplastic syndrome (MDS) and multiple myeloma.
Actinium is also developing its proprietary Actinium Warhead
Enabling (AWE) technology platform to utilize the highly
differentiated radioisotope actinium-225 with a wide range of
targets. AWE is being utilized in a collaborative research
partnership with Astellas Pharma, Inc.
More information is available at www.actiniumpharma.com and our
Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium Pharmaceuticals,
Inc.
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on
management's current expectations and are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with preliminary study results
varying from final results, estimates of potential markets for
drugs under development, clinical trials, actions by the FDA and
other governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Contact:
Actinium Pharmaceuticals, Inc.
Steve O'Loughlin
Vice President, Finance and Corporate Development
soloughlin@actiniumpharma.com
Investor Relations
Rx Communications Group
Paula Schwartz
917-322-2216
pschwartz@rxir.com
Susan A. Noonan
212-966-3650
investorrelations@actiniumpharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-host-webinar-showcasing-new-pipeline-initiative-focused-on-the-car-t-space-300714317.html
SOURCE Actinium Pharmaceuticals, Inc.